STAT

STAT+: Pharmalittle: Weight loss drugs cost much more in the U.S.; PBMs win a key victory over an Oklahoma law

A U.S. appeals court struck down key parts of an Oklahoma law designed to regulate the retail networks created by pharmacy benefit managers.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to catch, , , and . And what about you? There is still plenty of time to enjoy the great outdoors, so perhaps a ride in the country, a hike in the woods, or a stroll along city streets is in order. You could cool off in the local library or reach out to someone special. If none of this sounds appealing, you can always stay home and feel zen. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks